Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.53 |
| ▸ | CHRM5 | P08912 | 8/20 | 0.53 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.53 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.53 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | PLG | P00747 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12252660 | 0.85 | — | — | |
| SCHEMBL10881613 | 0.81 | CHRM2 (0.53) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2595906 | 0.76 | BCHE (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17147672 | 0.72 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL19101156 | 0.72 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL17147620 | 0.72 | CHRM2 (0.44) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5584863 | 0.71 | BCHE (0.49) | BCHEACHEHTR2CPLGGABRA1 | |
| SCHEMBL10901505 | 0.68 | BCHE (0.50) | BCHEACHEHTR2CPLGGABRA1 | |
| SCHEMBL3013313 | 0.68 | CHRM2 (0.62) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10901959 | 0.67 | ACHE (0.65) | BCHEACHEHTR2CPLGGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| EP-3030561-B1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LTD (IN) | 2017-01-11 | — | — | EP | disclosed |
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2016-06-23 | — | — | US | disclosed |
| EP-3030561-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | Cadila Healthcare Limited (IN) | 2016-06-15 | — | — | EP | disclosed |
| CN-105612154-A | N-cyanomethylamides as inhibitors of Janus Kinase | CADILA HEALTHCARE LTD | 2016-05-25 | — | — | CN | disclosed |
| WO-2015019365-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | CADILA HEALTHCARE LIMITED (IN) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176849-A1 | N-CYANOMETHYLAMIDES AS INHIBITORS OF JANUS KINASE | JAK1, JAK3, JAK2 | CHRM2 3386/4885CHRM4 3720/4885CHRM5 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.